Skip to content

IUI-PIV trial

A Randomized, Parallel Group, Comparative Study of the Effect of Intervention with Probiotic Products on the Vaginal Microbiota Following Vaginal Bacteriologic Examination of Artificial Insemination Patients

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs041240141
Enrollment
150
Registered
2024-12-11
Start date
2024-12-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General infertility General infertility

Interventions

Group A: Non-intervention group Group B: Standard treatment group (antibiotics only) Group C: New treatment group (antibiotics and probiotics III)
Probiotics

Sponsors

Takayama Erina
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Participants who plan to undergo IUI treatment for any of the following conditions abnormalities in the quantity or quality of sperm/semen, ejaculation disorders or sexual intercourse difficulties, sperm-cervical mucus incompatibility, or functional infertility. Age of female participants 18 to 43 years old. Participants who have provided written consent from themselves and their partners.

Exclusion criteria

Exclusion criteria: Individuals who have taken supplements or medications containing similar active ingredients to the investigational drug within 3 months before starting the drug. Individuals who have taken antibiotics for 5 days or more within 3 months before starting the investigational drug. Individuals who have participated in other clinical trials (clinical studies) within 3 months before starting the investigational drug that may have led to improvement in vaginal microbiota or other conditions. Individuals who have experienced diarrhea, vomiting, or allergies to the therapeutic drug. Individuals deemed unsuitable as study participants by the principal investigator or co-investigator.

Design outcomes

Primary

MeasureTime frame
The proportion of increase in Lactobacillus dominance to over 80% after intervention treatment in groups B and C.

Secondary

MeasureTime frame
The percentage of patients in Groups B and C whose Lactobacillus occupancy increased to 80% or more after the intervention, and the percentage of patients whose Lactobacillus occupancy improved after the intervention, by Lactobacillus occupancy. Percentage of cases that improved and those that did not improve (unchanged or worsened) after treatment in Groups B and C. Clinical pregnancy rates for the first IUI in groups B and C First IUI clinical pregnancy rate in group A and group B patients who improved to LD First IUI clinical pregnancy rate among group A and group C patients who improved to LD

Contacts

Public ContactHideaki Yajima

Mie University Hospital

fertility-repro@clin.medic.mie-u.ac.jp+81-59-232-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026